Treating hepatitis C virus in HIV patients: are side effects a real obstacle?
作者： Massimo Puoti , Paola Nasta , Alessandro Matti , Giampiero Carosi , Francesca Gatti
DOI:
关键词:
摘要: Hepatitis C virus-related long-term complications are nowadays a leading cause of morbidity and mortality in HIV-infected persons. According to international guidelines, all HIV/HCV-coinfected patients should be evaluated and, if eligible, treated with pegylated interferon plus ribavirin. The management anti-HCV treatment side effects, which may even more serious HIV patients, is very important minimize early discontinuations. purpose this review supply clinicians an update, provided by the most recent relevant literature, underlying mechanisms, incidence, advice about ribavirin effects HCV/HIV-coinfected patients.
参考文章(21)
Juan Gonzalez-Lahoz, Carmen De Mendoza, Michel P. De Baar, Vincent Soriano, Eveline Timmermans, Matilde Sanchez-Conde, Marije Buitelaar, Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin. Antiviral Therapy. ,vol. 10, pp. 557- 561 ,(2005)
David T Scadden, John J W Fangman, Anemia in HIV-infected adults: epidemiology, pathogenesis, and clinical management. Current hematology reports. ,vol. 4, pp. 95- 102 ,(2005)
Maurizio Bonacini, Stan Louie, Natalie Bzowej, Amy Rock Wohl, Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS. ,vol. 18, pp. 2039- 2045 ,(2004) , 10.1097/00002030-200410210-00008
Nicola De Maria, Alessandra Colantonl, Stefano Fagiuoli, Guang-Jun Liu, Brad K. Rogers, Fabio Farinati, David H. Van Thiel, Robert A. Floyd, Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radical Biology and Medicine. ,vol. 21, pp. 291- 295 ,(1996) , 10.1016/0891-5849(96)00044-5
Alfredo Alberti, Nathan Clumeck, Simon Collins, Wolfram Gerlich, Jens Lundgren, Giorgio Palù, Peter Reiss, Rodolphe Thiebaut, Ola Weiland, Yazdan Yazdanpanah, Stefan Zeuzem, (The ECC Jury), SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS Journal of Hepatology. ,vol. 42, pp. 615- 624 ,(2005) , 10.1016/J.JHEP.2005.03.003
NORIO HAYASHI, EIJI MITA, Fas system and apoptosis in viral hepatitis Journal of Gastroenterology and Hepatology. ,vol. 12, ,(1997) , 10.1111/J.1440-1746.1997.TB00504.X
Ondria C. Gleason, William R. Yates, M. Daniel Isbell, Michelle A. Philipsen, An open-label trial of citalopram for major depression in patients with hepatitis C. The Journal of Clinical Psychiatry. ,vol. 63, pp. 194- 198 ,(2002) , 10.4088/JCP.V63N0304
Luz Martín-Carbonero, Vincent Soriano, Eulalia Valencia, Javier García-Samaniego, Mariola López, Juan González-Lahoz, Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Research and Human Retroviruses. ,vol. 17, pp. 1467- 1471 ,(2001) , 10.1089/08892220152644160
K. Lindahl, R. Schvarcz, A. Bruchfeld, L. Stahle, Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. Journal of Viral Hepatitis. ,vol. 11, pp. 84- 87 ,(2004) , 10.1046/J.1365-2893.2003.00475.X
Hélène CF Côté, Zabrina L Brumme, Kevin JP Craib, Christopher S Alexander, Brian Wynhoven, Lillian Ting, Hubert Wong, Marianne Harris, P Richard Harrigan, Michael V O'Shaughnessy, Julio SG Montaner, None, Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients The New England Journal of Medicine. ,vol. 346, pp. 811- 820 ,(2002) , 10.1056/NEJMOA012035